Generics BulletinAt the midway point of 2023, dealmaking for big pharma had roared back to life following relative austerity in the previous two years, as credit became harder to come by, interest rates spiked, and le
In VivoAt the midway point of 2023, dealmaking for big pharma had roared back to life following relative austerity in the previous two years, as credit became harder to come by, interest rates spiked, and le
Pink SheetThe US FDA’s complete response letter for Eli Lilly and Company ’s mirikizumab for ulcerative colitis cements the company’s position as the most frequent big pharma recipient of CRLs for original app
Pink SheetThis edition of the Pink Sheet ’s Quality Lowdown takes a look at some of the bumps in the road and decisions made along the way in recent chemistry, manufacturing and controls reviews as assessors i